All In MedTech

Device Trial Radar · NCT04410146

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM)

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 319 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

319

Actual

Start

Nov 1, 2020

Primary completion

May 23, 2024

Study completion May 23, 2024

Sponsor

Lead sponsor
Balt USANot on our public-company list
Sponsor type
Industry
First posted
Jun 1, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

STEM Study is a pivotal, international, multi-center, prospective, randomized (1:1) controlled trial designed to provide an assessment of the safety and effectiveness of Middle Meningeal Artery (MMA) embolization with SQUID for the management of Chronic Subdural Hematoma (cSDH)

Conditions

  • Subdural Hematoma, Chronic

Interventions

  • SQUID EmbolizationDevice

    Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent

  • SQUID Embolization and Surgical EvacuationDevice

    Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical of the sub-dural hematoma

  • Surgical EvacuationProcedure

    Surgical evacuation of the sub-dural hematoma

  • Standard Medical ManagementOther

    Standard Medical Management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Endpoint-Number of Participants With Treatment FailureTime frame: On 180-day from intervention
  2. Primary Safety Endpoint-Number of Participants With Major Disabling Stroke or Any Death Within 30 Days of InterventionTime frame: Within 30-days from intervention

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Carondolet St. Joseph's

    Tucson, Arizona

  • Riverside Community Hospital

    Riverside, California

29 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.